|
Integratori non notificati Discutiamo di tutti gli integratori non vendibili in Italia
Ciao amico visitatore, cosa aspetti? Apri una discussione subito nella sezione Integratori non notificati |
|
LinkBack | Strumenti Discussione | Modalità Visualizzazione |
(#1)
|
|
All the Truth Member
Messaggi: 2,141
Data registrazione: Apr 2009
Località: Roma
Età: 36
|
Beta Ecdysterone -
22-07-2010, 02:03 AM
Beta EcdysteroneE' notificato? quali sono le sue proprietà ed eventuali usi? |
|
|
(#2)
|
|
Uncensored Magister
Messaggi: 25,331
Data registrazione: Jan 2005
Località: Kalepolis
Età: 48
|
24-07-2010, 09:55 PM
|
|
|
(#3)
|
|
All the Truth Member
Messaggi: 2,141
Data registrazione: Apr 2009
Località: Roma
Età: 36
|
25-07-2010, 12:49 AM
Grazie guru scemo io che non ho fatto la ricerca |
|
|
(#4)
|
|
All the Truth Member
Messaggi: 20,462
Data registrazione: Jun 2007
|
25-07-2010, 06:56 PM
io invece mi riservo il diritto di giudicare dato che avevo letto studi recenti con feed positivi anche sull'uomo sicuramente i risultati non sono come quelli vociferati ed acclamati nel passato cioe avere risultati e guadagni da aas senza sballare l'asse pero sembrerebbero funzionare il problema è che questa sostanza viene data sempre con il contagocce negli integratori dove è presente tipo e-bol pero sia con animal m-stack che con e-bol in america hanno ottenuto buoni risultati poi a confermare anche la cosa sembra sia nato un allenamento da abbinare insieme a questi prodotti un buon banco di prova sarebbe quello di usare uno di questi prodotti mantenendo la stessa alimentazione magari stando in ipercalorica con un buon numero di proteine cosi da vedere se effettivamente svolgono il loro lavoro |
|
|
(#5)
|
|
ParentalAdvisoryMember
Messaggi: 200
Data registrazione: Jul 2010
Località: Paleolitico
Età: 38
|
25-07-2010, 07:36 PM
J Int Soc Sports Nutr. 2006 Dec 13;3:19-27. Effects of methoxyisoflavone, ecdysterone, and sulfo-polysaccharide supplementation on training adaptations in resistance-trained males. Wilborn CD, Taylor LW, Campbell BI, Kerksick C, Rasmussen CJ, Greenwood M, Kreider RB. Human Performance Lab, University of Mary Hardin Baylor, Belton, TX. Abstract ABSTRACT : PURPOSE : Methoxyisoflavone (M), 20-hydroxyecdysone (E), and sulfo-polysaccharide (CSP3) have been marketed to athletes as dietary supplements that can increase strength and muscle mass during resistance-training. However, little is known about their potential ergogenic value. The purpose of this study was to determine whether these supplements affect training adaptations and/or markers of muscle anabolism/catabolism in resistance-trained athletes. METHODS : Forty-five resistance-trained males (20.5 +/- 3 yrs; 179 +/- 7 cm, 84 +/- 16 kg, 17.3 +/- 9% body fat) were matched according to FFM and randomly assigned to ingest in a double blind manner supplements containing either a placebo (P); 800 mg/day of M; 200 mg of E; or, 1,000 mg/day of CSP3 for 8-weeks during training. At 0, 4, and 8-weeks, subjects donated fasting blood samples and completed comprehensive muscular strength, muscular endurance, anaerobic capacity, and body composition analysis. Data were analyzed by repeated measures ANOVA. RESULTS : No significant differences (p > 0.05) were observed in training adaptations among groups in the variables FFM, percent body fat, bench press 1 RM, leg press 1 RM or sprint peak power. Anabolic/catabolic analysis revealed no significant differences among groups in active testosterone (AT), free testosterone (FT), cortisol, the AT to cortisol ratio, urea nitrogen, creatinine, the blood urea nitrogen to creatinine ratio. In addition, no significant differences were seen from pre to post supplementation and/or training in AT, FT, or cortisol. CONCLUSION : Results indicate that M, E, and CSP3 supplementation do not affect body composition or training adaptations nor do they influence the anabolic/catabolic hormone status or general markers of catabolism in resistance-trained males. PMID: 18500969 [PubMed - in process]PMCID: PMC2129166Free PMC Article C'è da dire che il dosaggio dell'ecdysterone usato dallo studio era più basso del dosaggio minimo solitamente usato (300mg). |
|
|
(#6)
|
|
All the Truth Member
Messaggi: 20,462
Data registrazione: Jun 2007
|
25-07-2010, 07:48 PM
io ne ho trovati 2 positivi 1 sui topi, con aumento della massa magra e muscolare anche se noi non siamo topi pero siamo sempre mammiferi il 2 invece se non ricordo male era sull'uomo ma iniettandolo |
|
|
(#7)
|
|
ParentalAdvisoryMember
Messaggi: 200
Data registrazione: Jul 2010
Località: Paleolitico
Età: 38
|
25-07-2010, 08:49 PM
REVIEW Effects and applications of arthropod steroid hormones (ecdysteroids) in mammals Laurence Dinan and René Lafont1 Department of Biological Sciences, University of Exeter, Exeter, Devon EX4 4PS, UK 1 Laboratoire Protéines: Biochimie Structurale et Fonctionnelle, Université Pierre et Marie Curie, 7 Quai St. Bernard, F-75252 Paris 05, France (Requests for offprints should be addressed to L Dinan who is now at 30 Hederman Close, Silverton, Nr. Exeter, Devon EX5 4HW, UK; Email: laurie@dinan.wanadoo.co.uk) ABSTRACT Zooecdysteroids (arthropod steroid hormones) regulate the development of arthropods and probably many other invertebrates. Phytoecdysteroids are analogues occurring in a wide range of plant species, where they contribute to the deterrence of phytophagous invertebrates. The purpose of this short review is to summarise findings on the occurrence, metabolism and pharmacological effects of ecdysteroids in mammalian systems and to draw attention to their potential applications, particularly in gene-switch technology, where ecdysteroid analogues (steroidal and non-steroidal) can be used as effective and potent elicitors. INTRODUCTION Ecdysteroids are the steroid hormones of arthropods, where they regulate moulting, metamorphosis, reproduction and diapause (Koolman 1989). They probably fulfil similar roles in many other invertebrate phyla, but these have not been so extensively investigated (Lafont 1997). Ecdysteroids are also present in 5–6% of plant species (Dinan 1995a), generally at far higher concentrations than those typically found in arthropods, where they are regarded as contributing to the deterrence of invertebrate predators (Lafont et al. 1991, Dinan 2001). The archetypal ecdysteroid in both arthropods and plants is 20-hydroxyecdysone (20E; Fig. 1), since it is the most commonly occurring and the most abundant, but a very wide range of structural analogues has been elucidated, especially from plant sources (Lafont et al. 2002). The first ecdysteroid (ecdysone; Fig. 2) was isolated in 1954 (Butenandt & Karlson 1954) and its structure was unambiguously identified only in 1965 (Huber & Hoppe 1965), with the result that research on ecdysteroids has generally lagged far behind that on the various classes of vertebrate steroid hormones, in spite of the fact that development in more than 90% of all animal species is dependent upon ecdysteroids. However, since the early reports of the occurrence of ecdysteroids in insects and plants, researchers have posed questions about the occurrence (from the diet), metabolism and possible effects of ecdysteroids in mammals. In the intervening period, a substantial body of evidence relevant to these questions has been obtained, suggesting that ecdysteroids may have significantly positive pharmacological properties. This is consistent with the use of several ecdysteroid-containing plant species in traditional medicines. The ready availability of large amounts of 20E from certain plant sources has led to a boom in recent years in its inclusion in many commercial anabolic preparations for body-builders and sportsmen. Further, since ecdysteroids are not endogenous products of mammalian metabolism and are non-toxic to mammals, they are also finding application as elicitors of novel gene-switch systems. With the intention of bringing this area to a wider audience of endocrinologists, we shall summarise the most significant findings. Also, we shall focus on the developments in this area since our previous review (Lafont & Dinan 2003), but the reader is referred to that review for a more extensive treatment of the relevant literature and the concepts. Occurrence of ecdysteroids in mammals Ecdysteroids are not regarded as products of mammalian metabolism. However, they can be detected in mammalian tissues and fluids as a consequence of dietary intake of ecdysteroid-containing plants (or insects in certain population groups) or infection by invertebrate parasites. Most crop plant species do not contain phytoecdysteroids, although both spinach (Spinacia oleracea) and quinoa (Chenopodium quinoa) do contain significant levels, especially in the seeds and younger leaves (Dinan 1995b). Ecdysteroids differ markedly from vertebrate steroid hormones in their polarity (polyhydroxylated), bulk (C27–C29) and shape (A/B-cis-ring junction), thus one would expect there to be little interaction with the steroid-hormone receptors or steroid-metabolising enzymes in mammals. Unfortunately, this has not been systematically verified. The mechanisms, by which any pharmacological effects of ecdysteroids in mammals are mediated, are presently unknown (but see below). Metabolism of ecdysteroids in mammals Injected or ingested ecdysteroids are rapidly cleared from the blood. In mice, ecdysone (Fig. 2) undergoes a complex array of metabolic reactions, including dehydroxylation (removal of the 14-OH) most probably by gut bacteria (cf. dehydroxylation of bile acids), reduction in the B-ring and epimerisation at C-3 (Lafont et al. 1988). In addition, when a 20,22-diol is present (as in 20E), side-chain cleavage can take place between C-20 and C-22 and the pattern of metabolites becomes very complex (Kumpun, Girault, Blais, Maria, Dauphin-Villemant, Yingyongnarongkul, Suksamrarn and Lafont, unpublished data). 14-Dehydroxylation also takes place in humans (Brandt 2003). Methods aimed at analysing 20E and its metabolites in human urine are presently being developed as anti-doping controls for humans and cattle (Tsitsimpikou et al. 2001, Le Bizec et al. 2002). Pharmacological effects of ecdysteroids on mammals Pharmacological tests were first performed on mammals (mice, rats) in the late 1960s to detect any harmful effects of ecdysteroids on vertebrate organisms, which could have precluded their use as insecticides. This was the starting point for many experiments, which reported a wide array of pharmacological effects of ecdysteroids on mammals (Sláma & Lafont 1995, Syrov 2000, Kholodova 2001, Báthori 2002, Lafont & Dinan 2003, Klein 2004, Báthori & Pongrácz 2005). Early pharmacological experiments First of all, it must be emphasised that the acute toxicity of ecdysteroids in mammals is very low: the LD50 for 20E is above 6 g/kg. The first reported effect of ecdysteroids on mammals was a stimulation of protein synthesis (translation) in vitro by liver polysomes prepared from rats having received 20E (or any of the other then available ecdysteroids). This effect was even used as a convenient bioassay for the presence of phytoecdysteroids in plant extracts during large-scale screening programmes (Otaka et al. 1969). At the same time, other authors analysed the distribution and metabolic fate of injected [3H]ecdysone (Hikino et al. 1972). These pioneering studies were followed by extensive studies on possible anabolic effects of ecdysteroids in rats (and humans). The general strategy was to compare the physical performance or biochemical parameters of animals having received 20E (or another ecdysteroid) over 1–3 weeks to controls or animals treated with a ‘classical’ anabolic steroid (testosterone or dianabol), and these experiments indicated a significant anabolic effect of ecdysteroids. Several ecdysteroid preparations have been designed for sportsmen (e.g. ‘Ekdisten’ or ‘Retibol’) containing quite small amounts of 20E (5 mg/tablet). Since those early times, the market for ecdysteroid-containing preparations has developed considerably, and is now especially aimed at bodybuilders; presently, ca. 300 ecdysteroid-containing products are available on the market, some of which contain large amounts of 20E, with formulations recommending up to 1 g daily intake, usually in combination with other known anabolic chemicals and/or included in a high-protein diet. The basis for all the Internet claims about the effects of ecdysteroids is not clear. However, the scientific literature shows that a significant body of experiments has indeed been performed, which describe various effects of ecdysteroids on mammals/humans, and have resulted in more than 50 patents for both internal and external use. The main findings are summarised below (for more details, see Lafont & Dinan 2003). Protein metabolism General stimulatory effects on protein synthesis have been shown for various ecdysteroids, including rubrosterone, a C-19 ecdysteroid lacking the whole side-chain (Fig. 2). These effects have been observed in mice injected with 5 mg ecdysteroid/kg and they seem to result from increased mRNA translation efficiency and not from increased mRNA synthesis (transcription) (Otaka et al. 1968, Syrov et al. 1978, Khimiko et al. 2000). Lipid metabolism Ecdysteroids have hypocholesterolamic effects (Mironova et al. 1982, Syrov et al. 1983), best explained by increased conversion of cholesterol into bile acids, reminiscent of the effect of oxysterols (Schroepfer 2000). In rats, low doses (10–50 µg/kg) of injected 20E do not affect cholesterolaemia, but reduce hepatic cholesterol levels (Lupien et al. 1969). In addition, dietary 20E (0.1 mg/kg per day) administered over 30 days reduces lipid peroxidation in membranes (Kuzmenko et al. 1997). Carbohydrate metabolism Pretreatment with ecdysteroids (i.p. injections of 0.5 mg/kg) may reduce hyperglycaemia induced by administration of glucagon or destruction (by alloxan treatment) of pancreatic islet ß-cells in mice and rats (Yoshida et al. 1971). Antidiabetic effects are also known for ecdysteroid-containing plants used in traditional medicine (e.g. Ajuga iva; Wessner et al. 1992) and ecdysteroid-containing preparations have been proposed for use against diabetes (Takahashi & Nishimoto 1992, Yang et al. 2001). Recent experiments in vitro with human hepatocytes have established that ecdysteroids (10–6–10–4 M) increase glucose consumption in an insulin-independent fashion (Chen et al. 2006). Effects on specific organs/systems The beneficial effects of ecdysteroids on the function of many organs have been reported. We will give a few examples. Muscle Ecdysteroids increase muscle mass by enhancing protein synthesis and decreasing protein catabolism. It has been suggested that the latter effect operates indirectly through a reduction of glucocorticoid levels (i.e. a reduction of stress), but this assumption has not been directly documented. Liver Ecdysteroids stimulate bile secretion in rats (Syrov et al. 1986), and they improve liver regeneration after chemically induced damage (Badal’yants et al. 1996). Kidney Dietary 20E (5 mg/kg) can restore normal glomerular filtration rate and suppress albuminuria in rats treated with a nephrotoxic mixture (Syrov & Khushbaktova 2001). Skin Ecdysteroid-containing liposomes improve skin quality by accelerating the healing of small wounds or burns (Meybeck & Bonté 1990) and have been marketed by Louis Vuitton-Möet Hennessy Company in several commercial cosmetics. 20E (2 x 10–4 M) promotes differentiation of human keratinocytes in vitro (Detmar et al. 1994) and this might explain its psoriasis-inhibiting activity (Inaoka et al. 1997). Brain Several actions of ecdysteroids on the central nervous system have been described; induction of enzymes related to neurotransmitter synthesis (glutamic decarboxylase; Chaudhary et al. 1969) or degradation (acetylcholinesterase; Catalán et al. 1984) and protection of neurons against the deleterious effects of various drugs (Aikake et al. 1996, Xu et al. 1999). Neuromodulatory effects of 20E (100 µM) on the GABAA receptor have also been reported (Tsujiyama et al. 1995, Okada et al. 1998). General comments Many more (beneficial) effects have, in fact, been described for injected or ingested ecdysteroids in mammals (see Lafont & Dinan 2003, Báthori & Pongrácz 2005). The weight of the accumulated evidence leaves little doubt that ecdysteroids do have effects on mammals. However, in many individual studies, the published data need to be further substantiated by more experimental evidence to be fully convincing. When crude or semi-purified plant extracts have been used, they do not demonstrate that the observed effects result (only) from ecdysteroids themselves. Whenever pure ecdysteroids have been used, the results are not always as spectacular as claimed in publicity promoting the use of these molecules for humans (but in this case, ecdysteroids are usually part of complex cocktails). Also, the statistical significance of results is questionable when small effects are observed with a low number of replicates and, in many instances, there is no clear-cut dose–response effect. Finally, we may consider as most convincing the unexpected data obtained by users of ecdysteroid-inducible gene systems (see below), which demonstrate ecdysteroid effects in control experiments, which means that exogenous insect ecdysteroid receptors are not required for some ecdysteroid effects to occur in mammalian/human cells (Constantino et al. 2001, Oehme et al. 2006). Possible mechanisms of action Besides their neuromodulatory effects on the GABAA receptor, which can easily be explained, the other numerous effects cannot be due to a single target. Moreover, some could be due to specific metabolites rather than the administered compound. Some transcriptional effects (perhaps caused by side-chain cleavage metabolites of ecdysteroids) can be expected to take place through binding to nuclear receptors (pregnane X receptor (PXR), constitutive androgen receptor (CAR) and liver X receptor (LXR)), which can bind a wide array of ligands, including various xenobiotics (Blumberg et al. 1998, d’Ursi et al. 2005, Handschin & Meyer 2005), but to our knowledge, as yet, there is no direct evidence for such binding. Recent data (Constantino et al. 2001, Oehme et al. 2006) provide convincing evidence that ecdysteroids evoke significant changes of gene expression in mammalian cells, resulting in the activation of the phosphatidylinositol-3-kinase/protein kinase B signal transduction (PI3K/Akt) pathway responsible for anti-apoptotic effects. We may also expect some rapid actions via membrane receptors: high affinity-binding sites have already been described using 20E bound to magnetic nanoparticles (Mykhaylyk et al. 2001), together with rapid effects on, e.g. prostaglandin synthesis (Kotsyuruba et al. 1995). Ecdysteroid receptors in arthropods Most actions of ecdysteroids are mediated by intracellular receptor complexes, although it should not be forgotten that some rapid actions are mediated by other mechanisms (Tomaschko 1999, Schlattner et al. 2006). The intracellular receptors from a range of arthropod species have been characterised and the active complex consists of two proteins: the ecdysteroid-receptor (EcR) protein and an ultraspiracle (USP) or retinoid X receptor (RXR) protein (Henrich 2005). All the above are members of the nuclear receptor superfamily, and USP and RXR are homologues (Laudet & Bonneton 2005). Members of this superfamily are characterised by a domain structure, consisting of an N-terminal A/B-domain involved in transcriptional activation, a DNA-binding C-domain, a hinge D-domain, the ligand-binding E-domain and an F-domain of unknown function (which is not present in all members of the superfamily). The C-domains of EcR/USP complexes interact with specific ecdysteroid-responsive elements (EcREs) in the promoter regions of ecdysteroid-responsive genes to alter gene transcriptional activity. X-ray crystallographic structures for lepidopteran (Billas & Moras 2005) and hemipteran (Carmichael et al. 2005) EcR E-domains, dipteran (Clayton et al. 2001) and lepidopteran (Billas et al. 2001) USP E-domains and dipteran EcR/USP C-domains (Devarakonda et al. 2003) have been elucidated. The ligand-binding domain (LBD) is specific for ecdysteroids and other classes of ecdysteroid agonists and antagonists (Dinan 2003, Dinan & Hormann 2005), such that the EcR/USP complex is not activated by vertebrate steroid, retinoid or thyroid hormones. USP is regarded as an orphan receptor, for which there is no definite ligand, but it has been suggested that juvenile hormones may interact with its LBD (Jones & Jones 2000, Fang et al. 2005). Further, when USP is replaced by RXR as EcRs partner, retinoids potentiate the activity of ecdysteroids (Saez et al. 2000). Since neither ecdysteroids nor EcR proteins are endogenous components of mammalian cells, this system can be used as the basis for the regulation of transfected genes possessing appropriate hormone responsive elements (HREs), by ecdysteroid receptors (also expressed from transfected genes) and the use of appropriate ecdysteroid (ant)agonists as elicitors, to generate an ‘ecdysteroid-inducible gene-switch system’. While, in theory, the native arthropod components (20E, EcR and EcRE; RXR is a constitutive component of many mammalian cell types) could be used, in practice, it is necessary to modify each of the exogenous components to optimise the properties and performance of the system to improve the sensitivity, specificity and strict temporal regulation of the transfected gene (see section ‘Ecdysteroid-inducible gene-expression systems’). Ecdysteroid-inducible gene expression systems The spatial and temporal control of heterologous gene expression is an area of major current interest with application to basic and applied biological and medical research, including gene therapy and functional genomics. Such ‘gene-switch’ systems should provide rapid, precise and reversible induction (or suppression) of the target gene(s), but not interfere with the complex endogenous regulatory networks of the host cells/tissues. Thus, the key characteristics of the system should be (Fussenegger 2001): The introduced regulatory machinery (transcription factor, elicitor) should be specific for the target gene(s) and not interfere with endogenous regulatory networks. The system should be inducible by low concentrations of elicitor in a dose-dependent manner, have a very low baseline expression in the absence of elicitor and a high induction ratio. The elicitor should be bio-available and readily penetrate to the target tissues. The action of the inducer should be reversible, either through metabolism or excretion, so as to permit switching-off of the effect and repeated cycles of induction. The components of the gene-switch system should not be immunogenic in the host. The design of the gene-switch system should be flexible enough to allow for different tissue applications and circumstances. Early ecdysteroid-related gene-switch systems (Christopherson et al. 1992, Yao et al. 1993) were based on the Drosophila melanogaster EcR (DmEcR), in conjunction with co-transfected USP or by using endogenous RXR as the heterologous partner. Thereafter, the activation potential and specificity for specific HREs were enhanced by modifying the activation and DNA-binding domains (No et al. 1996). A parallel system based on the Bombyx mori EcR (BmEcR) has been developed, and this has the advantage that BmEcR more readily partners with RXR than does DmEcR (Swevers et al. 1996, Suhr et al. 1998). Since then several Dm/Bm EcRs have been generated (Suhr et al. 1998), including one (DB-EcR; Hoppe et al. 2000), which is independent of recombinant RXR. A lentiviral vector system has been developed for the effective delivery of ecdysteroid-regulated genes into cells or animals (Galimi et al. 2005). Tight transcriptional regulation of foreign gene expression in insect cells has been obtained using a further system (Dai et al. 2005), consisting of (i) the DEF domains of the Choristoneura fumiferana EcR fused to the Saccharomyces cerevisiae GAL4 DNA-binding domain, (ii) the EF domains of mouse RXR fused to the acidic activation domains of baculovirus transactivators IE1 and IE0 and (iii) exogenously applied GS-E (RG-102240; Fig. 2). This system shows considerable promise for the controlled expression of toxic proteins, since any expression in the absence of inducer would result in cytotoxicity of the host cells. Most researchers’ interest in ecdysteroid-inducible gene expression systems is in the functional analysis of cloned genes, which can be put under the control of ecdysteroid-regulated promoters and transfected into mammalian cells. To this end, several commercial gene-switch kits have been developed, notably those produced by Invitrogen (Invitrogen by Life Technologies) and Rheogene (Intrexon). As elicitors, these systems use either the steroidal analogues muristerone A or ponasterone A, or a non-steroidal ecdysteroid agonist of the diacylhydrazine class (Nakagawa 2005), such as GS-E (Fig. 2). In the longer term, the intention is to generate systems capable of the independent and coordinated regulation of multiple genes in a tissue and, hence, gene therapy of disease states. Ecdysteroids and diacylhydrazines possess many properties that make them suitable as gene-switch elicitors. However, EcR LBDs, when expressed in mammalian cells, do not possess the same specificity or affinity as the same LBD in an insect system. Thus, much higher concentrations of active ecdysteroids are required and only certain analogues show significant activity. Thus, the endogenous hormone in insects, 20E, is hardly active in mammalian cells, and muristerone A and ponasterone A are required at concentrations of 1–10 µM to bring about a response when the effective concentrations in insect systems are much lower (e.g. EC50 values in the D. melanogaster BII bioassay are 2.2 x 10–8 and 3.1 x 10–10 M respectively; Dinan 2003). Identification of elicitors showing the same potency as these ecdysteroids in insect systems would considerably enhance the sensitivity and reduce the possibility of side-effects during gene therapy. This is being achieved by modifying LBDs of transgenic EcRs by site-directed mutagenesis to enhance the affinity for existing ligands (Palli et al. 2005a), modifying the partner RXR/USP (Palli et al. 2005b) or by comparative quantitative structure-activity relationship (QSAR) studies on the ligand specificities of ecdysteroid receptors expressed in insect and mammalian systems to identify the differences and to design more potent ligands (Dinan & Hormann 2005). Conclusions and prospects Most Internet claims for ‘spectacular’ effects of ecdysteroids on humans and other mammals are unsubstantiated or apocryphal. However, most reports in the scientific literature have demonstrated that the pharmacological effects of ecdysteroids in mammals are positive, and it is clear that ecdysteroids may influence/improve many physiological functions. Unfortunately, no extensive, systematic trials on any mammalian species have been published. Dietary intake of ecdysteroids is possible but limited for most humans, since the crop species which contain phytoecdysteroids are not extensively eaten. Thus, there may be a future for ecdysteroids as dietary supplements to contribute to human well-being (as ‘adaptogenic’ substances). However, more study is required to elucidate the metabolism of exogenous ecdysteroids in mammals and the biochemical modes of action of the parent ecdysteroids and their metabolites. Such studies are also important to underpin the use of ecdysteroid-induced gene switches. These systems possess considerable potential for basic biological studies of gene function and in gene therapy. Funding Research in the authors’ own research groups has been funded by BBSRC, CNRS, INTAS, Leverhulme Trust, MENESR and Rheogene LLC. There are no conflicts of interest which affect the impartiality of this review. |
|
|
(#8)
|
|
ParentalAdvisoryMember
Messaggi: 200
Data registrazione: Jul 2010
Località: Paleolitico
Età: 38
|
25-07-2010, 08:51 PM
References Aikake A, Matsumoto T & Yamaguchi Y 1996 Cerebral neuron protective agents containing ecdysteroids. Application JP 94–195279/19940819 (Chemical Abstracts 125: 1395). Badal’yants KL, Nabiev AN, Khushbaktova ZA & Syrov VN 1996 Mechanism of hepatoprotective action of ecdystene in acute heliotrine intoxication. Doklady Akademii Nauk Respubliki Uzbekistana 10 46–48. Báthori M 2002 Phytoecdysteroids effects on mammalians, isolation and analysis. Mini Reviews in Medicinal Chemistry 2 285–293.[CrossRef][Medline] Báthori M & Pongrácz Z 2005 Phytoecdysteroids – from isolation to their effects on humans. Current Medicinal Chemistry 12 153–172.[Web of Science][Medline] Billas IM & Moras D 2005 Ligand-binding pocket of the ecdysone receptor. Vitamins and Hormones 73 101–129.[Web of Science][Medline] Billas IM, Moulinier L, Rochel N & Moras D 2001 Crystal structure of the ligand-binding domain of the ultraspiracle protein USP, the ortholog of retinoid X receptors in insects. Journal of Biological Chemistry 276 7465–7474.[Abstract/Free Full Text] Blumberg B, Sabbagh W, Juguilon H, Bolado J, van Meter CM, Ong ES & Evans RM 1998 SXR, a novel steroid and xenobiotic-sensing receptor. Genes and Development 12 3195–3205.[Abstract/Free Full Text] Brandt F 2003 Pharmakokinetik und metabolismus des 20-Hydroxyecdysons im menschen. PhD Thesis, University of Marburg (Germany). Butenandt A & Karlson P 1954 Über die Isolierung eines Metamorphose-hormones der Insekten in kristallisierter Form. Zeitschrift für Naturforschung 9B 389–391.[Medline] Carmichael JA, Lawrence MC, Graham LD, Pilling PA, Epa VC, Noyce L, Lovrecz G, Winkler DA, Pawlak-Skrzecz E, Eaton RE et al. 2005 The X-ray structure of a hemipteran ecdysone receptor ligand-binding domain. Journal of Biological Chemistry 280 22258–22269.[Abstract/Free Full Text] Catalán RE, Aragones MD, Godoy JE & Martinez AM 1984 Ecdysterone induces acetylcholinesterase in mammalian brain. Comparative Biochemistry and Physiology 78c 193–195. Chaudhary KD, Lupien PJ & Hinse C 1969 Effect of ecdysone on glutamic decarboxylase in rat brain. Experientia 25 250–251.[CrossRef][Web of Science][Medline] Chen Q, Xia Y & Qiu Z 2006 Effect of ecdysterone on glucose metabolism in vitro. Life Sciences 78 1108–1113.[CrossRef][Web of Science][Medline] Christopherson KS, Mark MR, Bajaj V & Godowski PJ 1992 Ecdysteroid-dependent regulation of genes in mammalian cells by a Drosophila ecdysone receptor and chimeric transactivators. PNAS 89 6314–6318.[Abstract/Free Full Text] Clayton GM, Peak-Chew SY, Evans RM & Schwabe JWR 2001 The structure of the ultraspiracle ligand-binding domain reveals a nuclear receptor locked in an inactive conformation. PNAS 98 1549–1554.[Abstract/Free Full Text] Constantino S, Santo R, Gisselbrecht S & Gouilleux F 2001 The ecdysteroid inducible gene expression system: unexpected effects of muristerone A and ponasterone A on cytokine signalling in mammalian cells. European Cytokine Network 12 365–367.[Web of Science][Medline] Dai X, Willis LG, Palli SR & Thielmann DA 2005 Tight transcriptional regulation of foreign genes in insect cells using an ecdysone receptor-based inducible system. Protein Expression and Purification 42 236–245.[CrossRef][Web of Science][Medline] Detmar M, Dumas M, Bonté F, Meybeck A & Orfanos CE 1994 Effects of ecdysterone on the differentiation of normal human keratinocytes in vitro. European Journal of Dermatology 4 558–569. Devarakonda S, Harp JM, Kim Y, Ozyhar A & Rastinejad F 2003 Structure of the heterodimeric ecdysone receptor DNA-binding complex. EMBO Journal 22 5827–5840.[CrossRef][Web of Science][Medline] Dinan L 1995a A strategy for the identification of ecdysteroid receptor agonists and antagonists from plants. European Journal of Entomology 92 271–283. Dinan L 1995b Distribution and levels of phytoecdysteroids within individual plants of species of the Chenopodiaceae. European Journal of Entomology 92 295–300. Dinan L 2001 Phytoecdysteroids: biological aspects. Phytochemistry 57 325–339.[CrossRef][Web of Science][Medline] Dinan L 2003 Ecdysteroid structure-activity relationships. In Studies in Natural Products Chemistry, Bioactive Natural Products (Part J), vol 29 pp 3–71. Ed Attaur-Rahman. Amsterdam: Elsevier. Dinan L & Hormann RE 2005 Ecdysteroid agonists and antagonists. In Comprehensive Molecular Insect Science, vol 3, pp 197–242. Eds LI Gilbert, K Iatrou & SS Gill. Oxford: Elsevier Pergamon. d’Ursi P, Salvi E, Fossa P, Milanesi L & Rovida E 2005 Modelling the interaction of steroid receptors with endocrine disrupting chemicals. BMC Bioinformatics 6 (Suppl 14) S10. Fang F, Xu Y, Jones D & Jones G 2005 Interactions of ultraspiracle with ecdysone receptor in the transduction of ecdysone- and juvenile hormone-signaling. FEBS Journal 272 1577–1589.[Medline] Fussenegger M 2001 The impact of mammalian gene regulation concepts on functional genomic research, metabolic engineering, and advanced gene therapies. Biotechnology Progress 17 1–51.[CrossRef][Medline] Galimi F, Saez E, Gall J, Hoong N, Cho G, Evans RM & Verma IM 2005 Development of ecdysone-regulated lentiviral vectors. Molecular Therapy 11 142–148.[Web of Science][Medline] Handschin C & Meyer UA 2005 Regulatory network of lipid-sensing receptors: roles for CAR, PXR, LXR, and FXR. Archives of Biochemistry and Biophysics 433 387–396.[CrossRef][Web of Science][Medline] Henrich VC 2005 The ecdysteroid receptor. In Comprehensive Molecular Insect Science, vol 3, pp 243–285. Eds LI Gilbert, K Iatrou & SS Gill. Oxford: Elsevier Pergamon. Hikino H, Ohizumi Y & Takemoto T 1972 Absorption, distribution, metabolism and excretion of insect-metamorphosing hormone ecdysterone in mice. II. Chemical and Pharmaceutical Bulletin 20 2454–2458. Hoppe UC, Marban E & Johns DC 2000 Adenovirus-mediated inducible gene expression in vivo by a hybrid ecdysone receptor. Molecular Therapy 1 159–164.[CrossRef][Web of Science][Medline] Huber R & Hoppe W 1965 Die kristall- und molekülstrukturanalyse des insektenverpuppungshormones ecdyson mit der automatisierten faltmole-külmethode. Chemische Berichte 98 2403–2404.[Web of Science][Medline] Inaoka Y, Yamamoto M & Tsuji K 1997 Psoriasis inhibitors containing ecdysteroid analogs. Jpn. Kokai Tokkyo Koho JP 09 02,955 [97 02,955]. (Chemical Abstracts 126: 166507r). Jones G & Jones D 2000 Considerations on the structural evidence of a ligand-binding function of ultraspiracle, an insect homolog of vertebrate RXR. Insect Biochemistry and Molecular Biology 30 671–679.[CrossRef][Web of Science][Medline] Khimiko IN, Mitrokin YuI, Efremova OI & Sidorenko LI 2000 The influence of ecdysterone on the biosynthesis of proteins and nucleic acids in mouse organs. Khimiko-Farmatsevticheskii Zhurnal 34 3–5. Kholodova YuD 2001 Phytoecdysteroids: biological effects, application in agriculture and complementary medicine. Ukrainskii Biokhimicheskii Zhurnal 73 21–29.[Medline] Klein R 2004 Phytoecdysteroids. Journal of the American Herbalists Guild (fall/winter issue) 18–28. Koolman J (Ed) 1989 Ecdysone, pp 482. Stuttgart: Thieme Verlag. Kotsyuruba AV, Bukhanevich OM, Tuganova AV & Tarakanov SS 1995 Mechanisms of early effect of biologically active oxysterones calcitriol and ecdysterone, modulation of intracellular pools of arachidonic acid and products of its oxidative metabolism. Ukrainskii Biokhimicheskii Zhurnal 67 45–52.[Medline] Kuzmenko AI, Morozova RP, Nikolenko IA, Koniets GV & Kholodova YuD 1997 Effects of vitamin D3 and ecdysterone on free-radical lipid peroxidation. Biochemistry (Moscow) 62 609–612.[Medline] Lafont R 1997 Ecdysteroids and related molecules in animals and plants. Archives of Insect Biochemistry and Physiology 35 3–20.[Medline] Lafont R & Dinan L 2003 Practical uses for ecdysteroids in mammals including humans: an update. Journal of Insect Science 3 article 7, pp 30 (JIS: Lafont et.al. 3.7 2003). Lafont R, Girault JP & Kerb U 1988 Excretion and metabolism of injected ecdysone in the white mouse. Biochemical Pharmacology 37 1174–1177.[CrossRef][Web of Science][Medline] Lafont R, Bouthier A & Wilson ID 1991 Phytoecdysteroids: structures, occurrence, biosynthesis and possible ecological significance. In Insect Chemical Ecology, pp 197–214. Ed I Hrd. Czechoslovakia: Academia, Prague. Lafont R, Harmatha J, Marion-Poll F, Dinan L & Wilson ID 2002 Ecdybase, a free ecdysteroid database. Ecdybase does not support Netscape 4 Laudet V & Bonneton F 2005 Evolution of nuclear hormone receptors in insects. In Comprehensive Molecular Insect Science, vol 3, pp 287–318. Eds LI Gilbert, K Iatrou & SS Gill. Oxford: Elsevier Pergamon. Le Bizec B, Antignac JP, Monteau F & André F 2002 Ecdysteroids: one potential new anabolic family in breeding animals. Analytica Chimica Acta 473 89–97. Lupien PJ, Hinse C & Chaudhary KD 1969 Ecdysone as a hypocholesterolemic agent. Archives Internationales de Physiologie et de Biochimie 77 206–212.[Web of Science][Medline] Meybeck A & Bonté F 1990 Ecdysteroid-containing liposomes for wound healing and skin regeneration. Demande FR 2,637,182. (Chemical Abstracts 114: 30138r). Mironova VN, Kholodova YuD, Skatchkova TF, Bonda OP, Datsenko ZM & Govseeva NN 1982 Hypocholesterolemic effects of phytoecdysones in rat experimental hypercholesterolemia. Voprosy Meditsinskoi Khimii 28 101–105.[Web of Science][Medline] Mykhaylyk OM, Kotsuruba AV, Buchanevich OM, Korduban AM, Mengel EF & Gulaya NM 2001 Signal transduction of erythrocytes after specific binging of ecdysterone and cholesterol immobilized on nanodispersed magnetite. Journal of Magnetism and Magnetic Materials 225 226–234.[CrossRef] Nakagawa Y 2005 Nonsteroidal ecdysone agonists. Vitamins and Hormones 73 131–173.[Web of Science][Medline] No D, Yao TP & Evans RM 1996 Ecdysone-inducible gene expression in mammalian cells and transgenic mice. PNAS 93 3346–3351.[Abstract/Free Full Text] Oehme I, Bösser S & Zörnig M 2006 Agonists of an ecdysone-inducible mammalian expression system inhibit Fas ligand- and TRAIL-induced apoptosis in the human colon carcinoma cell line RKO. Cell Death and Differentiation 13 189–201.[CrossRef][Web of Science][Medline] Okada M, Ishihara K, Sasa M, Izumi R, Yajin K & Harada Y 1998 Enhancement of GABA-mediated inhibition of rat medial vestibular nucleus neurons by the neurosteroid 20-hydroxyecdysone. Acta Otolaryngologia 118 11–16. Otaka T, Uchiyama M, Okui S, Takemoto T, Hikino H, Ogawa S & Nishimoto N 1968 Stimulatory effect of insect metamorphosing steroids from Achyranthes and Cyathula on protein synthesis in mouse liver. Chemical and Pharmaceutical Bulletin 16 2426–2429. Otaka T, Uchiyama M, Takemoto T & Hikino H 1969 Stimulatory effect of insect metamorphosing steroids from ferns on protein synthesis in mouse liver. Chemical and Pharmaceutical Bulletin 17 1352–1355. Palli SR, Hormann RE, Schlattner U & Lezzi M 2005a Ecdysteroid receptors and their applications in agriculture and medicine. Vitamins and Hormones 73 59–100.[Web of Science][Medline] Palli SR, Zapitskaya MZ & Potter DW 2005b The influence of heterodimer partner ultraspiracle/retinoid X receptor on the function of ecdysone receptor. FEBS Journal 272 5979–5990.[Medline] Saez E, Nelson MC, Eshelman B, Banayo E, Koder A, Cho GJ & Evans RM 2000 Identification of ligands and coligands for the ecdysone-regulated gene switch. PNAS 97 14512–14517.[Abstract/Free Full Text] Schlattner U, Vafopoulou X, Steel CGH, Hormann RE & Lezzi M 2006 Non-genomic ecdysone effects and the invertebrate nuclear steroid hormone receptor EcR – new role for an ‘old’ receptor. Molecular and Cellular Endocrinology 247 64–72.[CrossRef][Web of Science][Medline] Schroepfer GJ Jr 2000 Oxysterols: modulators of cholesterol metabolism and other processes. Physiological Reviews 80 361–554.[Abstract/Free Full Text] Sláma K & Lafont R 1995 Insect hormones – ecdysteroids: their presence and actions in vertebrates. European Journal of Entomology 92 355–377. Suhr ST, Gil EB, Senut MC & Gage FH 1998 High level transactivation by a modified Bombyx ecdysone receptor in mammalian cells without exogenous retinoid X receptor. PNAS 95 7999–8004.[Abstract/Free Full Text] Swevers L, Cherbas L, Cherbas P & Iatrou K 1996 Bombyx EcR (BmEcR) and Bombyx USP (BmCF1) combine to form a functional ecdysone receptor. Insect Biochemistry and Molecular Biology 25 857–866. Syrov VN 2000 Comparative experimental investigations of the anabolic activity of ecdysteroids and steranabols. Pharmaceutical and Chemical Journal 34 193–197.[CrossRef] Syrov VN & Khushbaktova ZA 2001 The pharmacokinetics of phytoecdysteroids and nerobol on anaimals with experimental toxic renal damage. Eksperimental’naya in Klinicheskaya Farmakologiya 64 56–58. Syrov VN, Kurmukov AG & Sakhibov AD 1978 Effect of turkesterone and nerobol on the activity of the protein synthesizing system in mice liver. Voprosy Meditsinskoi Khimii 24 456–460.[Web of Science][Medline] Syrov VN, Khushbaktova ZA, Abzalova MKh & Sultanov MB 1983 On the hypolipidemic and antiatherosclerotic action of phytoecdysteroids. Doklady Akademii Nauk Uzbeckoy SSR 9 44–45. Syrov VN, Nabiev AN & Sultanov MB 1986 The effect of phytoecdysteroids on the bile secretion function of the liver in normal rats and in animals with experimental hepatitis. Farmakologiya i Toksikologiya 49 100–103. Takahashi H & Nishimoto K 1992 Antidiabetic agents containing ecdysterone or inokosterone. Jpn Kokai Tokkyo Koho JP 04,125,135 [92 124,135]. (Chemical Abstracts 117: 84874b). Tomaschko K-H 1999 Nongenomic effects of ecdysteroids. Archives of Insect Biochemistry and Physiology 41 89–98.[CrossRef] Tsitsimpikou C, Tsamis GD, Siskos PA, Spyridaki MH & Georgakopoulos CG 2001 Study of excretion of ecdysterone in human urine. Rapid Communications in Mass Spectrometry 15 1796–1801.[CrossRef][Web of Science][Medline] Tsujiyama S, Ujihara H, Ishihara K & Sasa M 1995 Potentiation of GABA-induced inhibition by 20-hydroxyecdysone, a neurosteroid, in cultured rat cortical neurons. Japanese Journal of Pharmacology 68 133–136.[Medline] Wessner M, Champion B, Girault J-P, Kaouadji M, Saïdi B & Lafont R 1992 Ecdysteroids from Ajuga iva. Phytochemistry 31 3785–3788.[CrossRef] Xu N, Guo Y, Rui W, Li Z & Li X 1999 Protective effect of ecdysterone on amnesia induced by diazepam and alcohol. Zhongguo Yaolixue Yu Dilixue Zazhi 13 119–122. Yang C, Zhang G, Liu X & Wang C 2001 Oral antidiabetic compositions containing ß-ecdysone from Cyanothis arachnoides. Appl. CN-2000–10637/20000612 (Chemical Abstracts 135: 127188). Yao TP, Forman BM, Jiang Z, Cherbas L, Chen JD, McKeown M, Cherbas P & Evans RM 1993 Functional ecdysone receptor is the product of EcR and ultraspiracle genes. Nature 366 476–479.[CrossRef][Medline] Yoshida T, Otaka T, Uchiyama M & Ogawa S 1971 Effect of ecdysterone on hyperglycemia in experimental animals. Biochemical Pharmacology 20 3263–3268.[CrossRef][Web of Science][Medline] |
|
|
(#9)
|
|
All the Truth Member
Messaggi: 2,141
Data registrazione: Apr 2009
Località: Roma
Età: 36
|
25-07-2010, 10:10 PM
Grazie ragazzi per gli interventi comunque immagino che degli effetti collaterali si debbano avere o no? |
|
|
(#10)
|
|
All the Truth Member
Messaggi: 1,812
Data registrazione: Sep 2009
Età: 31
|
25-07-2010, 10:17 PM
no io non credo che prendendo dosi come quelle dell' m-stack avrai effetti collaterali anzi avrai solo effetti placebo dato che secondo me le dosi negli integratori sono basse e insignificanti per un soggetto giovane |
|
|
(#11)
|
|
All the Truth Member
Messaggi: 2,141
Data registrazione: Apr 2009
Località: Roma
Età: 36
|
25-07-2010, 10:21 PM
Premetto che non lo chiedevo perchè devo usarlo semplicemente avevo curiosità dato che solitamente quando in mezzo si mettono meccanismi anche ormonali effetti negativi ci sono |
|
|
(#12)
|
|
All the Truth Member
Messaggi: 1,812
Data registrazione: Sep 2009
Età: 31
|
25-07-2010, 10:31 PM
co ste dosi non succede niente purtroppo llol |
|
|
(#13)
|
|
ParentalAdvisoryMember
Messaggi: 200
Data registrazione: Jul 2010
Località: Paleolitico
Età: 38
|
25-07-2010, 11:17 PM
Non si è neppure sicuri se funziona, se pure da problemi... allora è proprio un integratore ottimo ma a conti fatti qualcuno lo ha mai provato? |
|
|
(#14)
|
|
All the Truth Member
Messaggi: 1,812
Data registrazione: Sep 2009
Età: 31
|
25-07-2010, 11:57 PM
io ho provato l'm-stack e sinceramente l'm-stack di effett isu di me ne ha fatti ben pochi lol |
|
|
Strumenti Discussione | |
Modalità Visualizzazione | |
|
|